Natural killer cell activation induced by interleukin-12, interleukin-15, and interleukin-18 stimulation

Activation of natural killer (NK) cells via combined stimulation with interleukin-12, interleukin-15, and interleukin-18 induces a "memory-like" phenotype characterized by enhanced effector functions, increased cytotoxicity, and increased production of cytokines such as interferon gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and IL-8. This synergistic stimulation generates NK cells with improved responses upon restimulation, improving immunity against infections and cancer. These "cytokine-induced memory-like" NK cells have become a promising area for cancer immunotherapy, though the target is a cellular phenotype arising from signaling through several cytokine receptors rather than a single molecular entity. Currently, clinical and research applications focus on adoptive transfer of these pre-activated NK cells or pharmacologic administration of the cytokines. The main challenges relate to safety and specificity, including the risk for systemic inflammation and off-target effects.

Other names

Cytokine-induced memory-like NK cell activationCIML NK cell activationNK cell preactivation by IL-12/IL-15/IL-18Tripartite cytokine-stimulated NK cell activation

Activation of NK cells via binding and signaling through IL-12 receptor (IL-12Rβ1/IL-12Rβ2), IL-15 receptor, and IL-18 receptor. Induction of STAT4 and T-bet transcription factors, leading to IFN-γ, TNF-α, and other cytokine/chemokine production. Synergy among the three cytokines results in maximal cytotoxicity, "memory-like" features, and enhanced effector function.